A research paper by scientists at Hangzhou Dianzi University presented a HER2+ breast cancer response prediction model based on hierarchical tissue specific modeling of pathological images.

The research paper, published on Apr 22, 2026 in the journal Cyborg and Bionic Systems.

A research paper by scientists from Southern University of Science and Technology developed a near-infrared (NIR) light-activated biomimetic nanomotor for targeted nitric oxide (NO) delivery and synergistic cancer therapy.

The new research paper, published on Apr. 24 in the journal Cyborg and Bionic Systems, developed a new light‑activated nanomotor platform combines photothermal therapy, chemodynamic therapy, and nitric oxide (NO) gas therapy in one tiny, tumor‑hunting vehicle.

As AI is being widely tested in medicine, scientists at the University of Auckland, Auckland City Hospital, and Matai Medical Research Institute in New Zealand have analyzed the current landscape of AI models for meningioma (a cancer of the brain’s soft cover) segmentation from MRI scans, and its path ahead. Their key finding is that advanced model architecture has considerably contributed to tumor detection sensitivity, rather than data characteristics, imaging modalities, or preprocessing.  

Dendritic mesoporous silica-lanthanide fluoride (DMS-CeF₃:Tb) nanocomposites with a pomegranate-like architecture have been fabricated through a facile in situ enrichment strategy. The strong single-particle luminescence and long photoluminescence lifetime of DMS-CeF₃:Tb nanoprobes enabled an ultrasensitive immunoassay for prostate specific antigen (PSA) with a detection limit of 41 fg mL^-1, which represents a 976-fold improvement over a commercial PSA enzyme-linked immunosorbent assay kit. Validation with PCa serum samples revealed a strong correlation with the hospital’s electrochemiluminescence immunoassay, confirming the clinical applicability of the nanoprobes. Additionally, targeted imaging and in vitro detection of cervical cancer cells were realized utilizing biotinylated DMS-CeF₃:Tb nanoprobes, enabling rapid cancer screening. These findings reveal the great potential of DMS-CeF₃:Tb as an efficient nano-bioprobe for early cancer diagnosis.